Creative Touch Permanent Makeup and Aesthetics

PDRN is a DNA-derived biopolymer prepared from salmon or trout sperm cells – specifically referring to the shorter-chain fragment preparations in the 50–1,500 kDa molecular weight range, with a peak distribution around 132 kDa. ^[3] It is the earlier and more clinically established term, predating the broader polynucleotide (PN) category by several years and carrying a longer medical research trail across wound healing, diabetic foot ulcers, ischaemic tissue repair, tendon regeneration, and orthopaedic applications before entering aesthetics practice. ^[2]

PDRN vs PN: The Structural Distinction

PDRN and PN are not synonyms – they are structurally distinct polymers that are considered bioequivalent in clinical effect. jcasonline.com The primary distinction is fragment length: PDRN consists of shorter DNA chains (typically under 1,500 kDa); PN encompasses longer chains extending up to 10,000 kDa in some modern preparations. A 2025 head-to-head comparative review confirmed this structural difference has at least one directly measurable clinical consequence: PDRN’s lower molecular weight and viscosity means it is administered through finer, higher-gauge needles than PN preparations, which require wider-bore needles due to their longer-chain viscosity. ^[1] Both act through the identical A2AR mechanism; the terms continue to be used interchangeably throughout much of the clinical literature despite the structural distinction. ^[1]

Molecular Weight and Tissue Effects

The 2025 bridging review noted that medium molecular weight PDRN – the “classic” preparation around 132 kDa – demonstrated less lipid accumulation, increased collagen composition, and increased cell migration compared to both lower and higher molecular weight variants in wound models. ^[2] This suggests molecular weight optimisation within the PDRN range is not pharmacologically neutral – a detail relevant to product selection that the broader PN category does not capture.

Registered Drug Status and Medical History

PDRN holds registered drug status in several jurisdictions – a distinction that reflects both the depth of its pre-aesthetics medical evidence base and the rigour of its manufacturing and purification standards. ^[3] Its A2AR binding property is described as linked specifically to DNA origin, molecular weight, and manufacturing process – meaning the pharmacological activity is not simply a property of DNA fragments in general but of a defined preparation within a defined molecular weight range. This regulatory and pharmacological specificity is what distinguishes PDRN from the broader, more heterogeneous PN category in formal clinical and regulatory contexts, even whilst their aesthetic clinical effects are bioequivalent in practice.

Rejuran

Rejuran is the dominant branded PDRN aesthetic product – a purified salmon-derived PN/PDRN preparation with its own clinical evidence base, including a Korean phase III split-face RCT confirming improvements in skin elasticity and texture, periocular split-face studies showing superior hydration and elasticity vs. HA comparators, and an objective measurement study confirming crow’s feet improvement via CFGS and 3D image analysis. ^[1] Rejuran is the PDRN brand most likely to be encountered by name in client searches and consultations; it resolves to this entity and, for full mechanism and protocol content, to the Polynucleotides (PN) entity.

→ See: Polynucleotides (PN) for the full A2AR mechanism description, macrophage- fibroblast axis, MMP suppression pathway, clinical context, and combination protocols.